Celecoxib has been shown to enhance the chemosensitivity of platinum-treated GC cells through the inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) and Bcl2 expression via the ERK1/2 and P38 signaling axis. The gene discussed is PTGS2; the disease is gastric cancer.